New York, January 21, 2026, 18:56 EST — After-hours
- AbbVie shares finished Wednesday roughly 1% higher, lingering around $216 in late trading.
- Bernstein’s Courtney Breen stuck with a Market Perform rating, setting the target at $225
- Investors are focused on AbbVie’s Feb. 4 earnings report and its forecast for 2026
AbbVie Inc. shares climbed 0.99% to $216.15 Wednesday, fluctuating between $211.57 and $218.00 during the session. After-hours trading saw little movement. Around 10.7 million shares exchanged hands, matching the drugmaker’s typical volume. (StockAnalysis)
The timing is crucial as AbbVie approaches its full-year and fourth-quarter earnings report in two weeks. So far, the stock has been priced more on its 2026 outlook than any recent news. Investors are eager for confirmation that the company’s newer growth engines can sustain momentum amid rising pressure on its older products.
Wall Street’s attention to “neutral” ratings is growing. Bernstein SocGen Group analyst Courtney Breen held firm on a Market Perform rating for AbbVie, signaling returns roughly in line with the market or its peers. She maintained a $225 price target, about 4% above Wednesday’s closing price. (Streetinsider)
AbbVie rallied amid a wider bounce in U.S. equities Wednesday, following steep losses the day before. The S&P 500 climbed 1.16%, while the Nasdaq added 1.18%, driven by easing worries over tariffs sparked by President Donald Trump’s comments on Greenland, Reuters reported. (Reuters)
AbbVie will release its results on Feb. 4 ahead of the U.S. market open and hold a webcast conference call at 8 a.m. Central time, the company announced. (AbbVie News Center)
Ahead of the release, traders will focus on any changes in outlook for AbbVie’s newer immunology drugs and how steady demand remains for its main franchises. It’s the guidance and insights on product mix that usually drive the stock more than minor quarterly earnings surprises.
Policy uncertainty still looms over the group. Earlier this month, AbbVie announced a voluntary deal with the Trump administration, promising “low prices” in Medicaid alongside a commitment to invest $100 billion in U.S. R&D and capital over the next 10 years. In return, the company secured relief from tariffs and pricing mandates under the agreement. “AbbVie’s mission is to make a remarkable impact for the patients we serve,” CEO Robert A. Michael said when the deal was unveiled. (AbbVie News Center)
Investors, however, are still waiting on more specifics, as the company says key terms of the deal remain under wraps. A drop in realized prices or a tougher stance on U.S. drug pricing could pressure margins right when AbbVie is fighting to hold its ground in crowded markets.
The next major event is Feb. 4, when earnings drop before the bell alongside management’s 2026 guidance. Investors will focus on sales trends for key drugs and any fresh insights on pricing or competitive challenges.
